WebDoctor Encyclopedia

Childhood Primary bone tumours Soft-tissue sarcomas

Mesenchymal chondrosarcoma

Mesenchymal chondrosarcoma is a rare, high-grade cartilage-forming cancer of bone or soft tissue that mainly affects teenagers and young adults. It carries a HEY1::NCOA2 fusion and is treated with surgery, often with chemotherapy and radiotherapy.

Medically reviewed Last reviewed November 15, 2026

What is mesenchymal chondrosarcoma?

Mesenchymal chondrosarcoma is a rare, high-grade cancer that can start in bone or in soft tissue. It belongs to the chondrosarcoma family, the group of cancers that make cartilage. Unlike the common, slow-growing types of chondrosarcoma, it is fast-growing and tends to affect teenagers and young adults.

Under the microscope the tumour has two parts. Most of it is made of small, round, primitive cells that look a little like Ewing sarcoma. Scattered among them are islands of cartilage. This mixture of primitive cells and cartilage is the hallmark of the disease.

Nearly all of these tumours carry a specific gene fusion called HEY1::NCOA2. Finding this fusion confirms the diagnosis and separates the tumour from look-alikes (Baldi et al., 2026).

How it differs from conventional chondrosarcoma

Most chondrosarcomas are conventional chondrosarcomas, described on our page on chondrosarcoma. These usually affect older adults, grow slowly in the pelvis or long bones, and respond poorly to chemotherapy.

Feature Conventional chondrosarcoma Mesenchymal chondrosarcoma
Share of chondrosarcomas About three in four Around 2%
Typical age Middle-aged and older adults Teenagers and young adults
Site Bone only Bone or soft tissue, including the head and neck
Cells Cartilage throughout Small round cells with cartilage islands
Gene change Often IDH1 or IDH2 HEY1::NCOA2 fusion
Chemotherapy Little benefit Often used

Hameed (2021) lists mesenchymal chondrosarcoma as roughly 2% of all chondrosarcomas, while other authors give a range of 2-10% (Qi et al., 2022).

1. Key facts at a glance

Feature Details
Type of cancer High-grade sarcoma with small round cells and cartilage
How common Very rare
Typical age Peak from the teenage years to the 30s
Common sites Jaw and skull, spine, ribs, pelvis; soft tissue of the head, neck, brain coverings and limbs
Gene change HEY1::NCOA2 fusion
Main treatment Wide surgical removal
Other treatments Chemotherapy and radiotherapy in many patients
Typical spread Lungs and bone, sometimes many years after diagnosis
Outlook Variable; late relapse is common, so long-term follow-up is needed

2. Types

By site of origin

Type Typical locations Notes
Skeletal (bone) Jaw bones, skull, ribs, spine, pelvis Often found as a painful swelling
Extraskeletal (soft tissue) Coverings of the brain and spine, eye socket, thigh and other soft tissues Can arise far from bone

In a German study of young patients aged 25 or under, 11 of 15 tumours were outside bone and six were in the head and neck (Dantonello et al., 2008).

By microscopic appearance

Pattern Description
Classic biphasic Primitive round cells with clear islands of cartilage
Cartilage-poor Few cartilage islands; harder to diagnose on a small biopsy
Spindle cell areas Some tumours contain elongated cells

3. Causes and risk factors

The cause is not known. The disease arises from a gene change that happens by chance in a single cell.

Factor Notes
HEY1::NCOA2 fusion Present in the tumour cells only; not inherited
Age Mainly adolescents and young adults
Sex Both sexes
Previous radiotherapy No clear link
Inherited syndromes None known
Lifestyle No known link

What does the fusion do?

Two genes, HEY1 and NCOA2, break and join together. The new combined gene makes a protein that switches on growth programmes normally used during early development. Laboratory work showed that the fusion protein boosts cell growth and raises the activity of the PDGF and AKT signalling pathways, which might become targets for future drugs (Qi et al., 2022).

4. How does it look

On scans

Scan Typical findings
X-ray A destructive bone lesion, sometimes with speckled or ring-like calcification from cartilage
CT Shows bone destruction and calcified spots
MRI Defines the soft tissue mass and its relation to nerves, vessels and the brain
PET-CT Helps with staging
Bone scan May be used to look for spread to other bones

Under the microscope

Feature Description
Small round cells Sheets of primitive cells with little cytoplasm
Cartilage islands Well-formed cartilage that may calcify
Branching vessels Thin-walled, branching “staghorn” blood vessels
Stains SOX9 and CD99 often positive; NKX2.2 may be positive
Molecular test HEY1::NCOA2 fusion by sequencing or FISH

The small round cells can make the tumour look like Ewing sarcoma, synovial sarcoma or a solitary fibrous tumour, especially on a small biopsy. Molecular testing helps to sort these out.

5. Symptoms

Symptoms depend on where the tumour grows.

Common symptoms

  • Pain in a bone or the affected area
  • A lump or swelling, often growing over weeks or months
  • Stiffness or reduced movement of a nearby joint

Symptoms by site

Site Possible symptoms
Jaw Swelling of the face, loose teeth, numbness of the lip or chin
Skull and brain coverings Headaches, seizures, weakness, vision changes
Eye socket Bulging of the eye, double vision
Spine Back pain, numbness or weakness in the legs, bladder or bowel problems
Ribs or chest Chest wall lump, pain on breathing
Limbs Painful swelling, limp

When to seek medical advice

See a doctor about any persistent bone pain, particularly at night, or a lump that is growing. Seek urgent help for sudden weakness, loss of bladder or bowel control, or a new seizure.

6. Diagnosis

Step What is done
History and examination Assesses symptoms and the lump
X-ray and MRI Images the primary tumour
Core needle biopsy Planned by the sarcoma surgeon so the track can be removed later
Pathology review Ideally at a specialist sarcoma laboratory
Molecular testing Confirms HEY1::NCOA2 fusion
CT of the chest Looks for lung spread
PET-CT or bone scan Looks for spread elsewhere

Staging

Stage group Simplified meaning
Localised Tumour limited to its site of origin
Locally advanced Large tumour or spread into nearby structures
Metastatic Spread to lungs, bones or other organs

All mesenchymal chondrosarcomas are treated as high-grade tumours.

7. Treatment

Treatment is planned by a bone and soft tissue sarcoma team. Because the disease is so rare, there are no randomised trials, and plans are based on case series.

Surgery

Aspect Details
Aim Complete removal with a wide margin of healthy tissue
Limbs Limb-sparing surgery is usually possible
Jaw and skull Specialist head and neck or neurosurgical teams; reconstruction may be needed
Spine Complex surgery, sometimes combined with radiotherapy

Complete removal matters. In the German series, seven of eight young patients whose tumours were fully removed at first surgery stayed disease-free, compared with four of seven whose surgery was incomplete (Dantonello et al., 2008).

Chemotherapy

Regimen Evidence summary
Ewing-type combinations (vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide) Often used before and after surgery in fit patients
Other anthracycline regimens Responses in about a quarter of patients in an Italian series
High-dose ifosfamide No responses in that series
Trabectedin Kept disease stable in a small number of patients with advanced disease

The Italian Sarcoma Group found that responses to anthracycline treatment were closer to those of soft tissue sarcomas than of Ewing sarcoma. It still suggested that Ewing-type chemotherapy be considered around surgery (Baldi et al., 2026).

Radiotherapy

Situation Role
Incomplete margins Reduces the risk of local regrowth
Tumours that cannot be removed Main local treatment
Skull base and spine Proton therapy may be used to protect nearby structures
Symptom relief For painful bone or other metastases

Treatment of relapse

Situation Options
Single lung nodules Surgical removal
Local recurrence Further surgery or radiotherapy
Widespread disease Chemotherapy, trabectedin, clinical trials

A typical treatment pathway

Phase What happens Typical length
Diagnosis and staging Scans, biopsy, molecular testing 2-4 weeks
Chemotherapy before surgery Several cycles, if recommended About 3-4 months
Surgery Wide removal and any reconstruction Hospital stay of days to weeks
Treatment after surgery More chemotherapy and, if needed, radiotherapy Several months
Rehabilitation Physiotherapy and return to normal activities Months

Side effects

Treatment Possible side effects
Surgery Pain, wound problems, reduced movement, need for reconstruction
Chemotherapy Hair loss, sickness, infection risk, fertility effects, heart effects with doxorubicin
Radiotherapy Skin changes, tiredness, local scarring, growth effects in young people

8. Outlook (prognosis)

The outlook varies widely. A key feature of this cancer is its tendency to return late, sometimes more than ten years after treatment. Older reports gave 10-year survival rates below 50% (Dantonello et al., 2008).

Factor Effect
Localised disease at diagnosis Better outlook
Complete surgical removal Better outlook
Metastases at diagnosis Poorer outlook
Younger age Some series report better results in young patients

In the German young-patient series, about two in three were alive at ten years (Dantonello et al., 2008). In the Italian series, patients with localised disease who had Ewing-type chemotherapy had a 5-year survival of 95%, though the numbers were small (Baldi et al., 2026).

Why late relapse matters

Many cancers that stay away for five years are unlikely to come back. Mesenchymal chondrosarcoma is different. Spread to the lungs or bones can appear a decade or more after the first treatment. This is why sarcoma teams keep seeing patients for many years and why any new symptom, even long after treatment, should be reported.

Interestingly, the German series of young patients did not see these late relapses during almost ten years of follow-up. All four recurrences happened within four years (Dantonello et al., 2008). It is not yet clear whether young patients truly behave differently or whether this reflects the small numbers.

9. Follow-up

Period Typical checks
Years 1-3 Clinic visit and chest CT every 3-4 months; MRI of the primary site
Years 4-5 Every 6 months
Years 5-10 and beyond Yearly, as late relapse is common
Late effects clinic For young people treated with chemotherapy or radiotherapy

10. Living with mesenchymal chondrosarcoma

  • Attend follow-up for many years, even when you feel well
  • Work with physiotherapists to regain strength and movement after surgery
  • Discuss fertility preservation before chemotherapy
  • Keep up with school, college or work with support from your team
  • Ask about late effects, such as heart or hearing checks after chemotherapy
  • Seek support from sarcoma charities and teenage and young adult cancer services

For teenagers and young adults

A cancer diagnosis in your teens or twenties can disrupt education, relationships and plans. Many hospitals have teenage and young adult units with youth workers, psychologists and peer support. Ask your team how to access them.

11. Frequently asked questions

Question Answer
Is it the same as Ewing sarcoma? No; it can look similar, but it has a different gene fusion and contains cartilage
Is it inherited? No; the gene fusion arises only in the tumour
Why is follow-up so long? The cancer can come back many years later
Will I need chemotherapy? Often, especially for young patients and larger tumours
Can I keep my limb? Most limb tumours can be removed without amputation
Can I play sport after treatment? Often yes, once healing allows; your surgeon and physiotherapist will advise on contact sports
Will I need a prosthesis? Only if the tumour cannot be removed while keeping the limb, which is uncommon
Are there targeted drugs? Not yet approved; research is exploring pathways switched on by the fusion

12. Questions to ask your care team

  • Has the HEY1::NCOA2 fusion been confirmed?
  • Has the cancer spread anywhere?
  • Can the tumour be removed completely?
  • Do you recommend chemotherapy before or after surgery?
  • Will I need radiotherapy?
  • How will treatment affect my fertility, growth or appearance?
  • How long will follow-up last?
  • Is there a teenage and young adult service or a clinical trial I could join?
  • Who should I contact if I notice a new symptom between visits?

Resources

  1. Baldi, G.G. et al. (2026) ‘Activity of chemotherapy in mesenchymal chondrosarcoma: a multicentre retrospective analysis within the Italian Sarcoma Group network’, ESMO Open, 11(2), 106080.
  2. Dantonello, T.M. et al. (2008) ‘Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults: experiences of the CWS and COSS study groups’, Cancer, 112(11), pp. 2424-2431.
  3. Hameed, M. (2021) ‘Malignant cartilage-forming tumors’, Surgical Pathology Clinics, 14(4), pp. 605-617.
  4. Qi, W. et al. (2022) ‘Genomic profiling identifies genes and pathways dysregulated by HEY1-NCOA2 fusion and shines a light on mesenchymal chondrosarcoma tumorigenesis’, Journal of Pathology, 257(5), pp. 579-592.
  5. National Cancer Institute (2026) Childhood Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/child-soft-tissue-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.